Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Biotron Ltd (BITRF) Message Board

Biotron shares double on achieving a breakthrough

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 6
(Total Views: 351)
Posted On: 09/29/2018 3:40:47 PM
Posted By: drmkj2
Biotron shares double on achieving a breakthrough towards curing HIV-1 infection

2018-09-28 12:43:00
The company’s shares are trading about 121% higher intra-day, at 4.2 cents.

Biotron Limited (ASX:BIT) has revealed a successful outcome to the phase II trial of its lead drug BIT225 in HIV-infected patients in combination with current antiretroviral drugs.

The results show that there are significant immunological benefits in patients receiving antiretroviral drugs with 200 mg BIT225 compared to antiretroviral drugs plus placebo.

Unique advantage of BIT225

Current antiretroviral drugs are extremely efficient at clearing the HIV-1 virus.

However, these antiretroviral drugs do not clear cellular reservoirs.

The data from the trial is consistent with the targeting and eradication of HIV-1 virus from these key reservoir cells in the BIT225-treated patients.

Biotron managing director Dr Michelle Miller said: “We know that antiretroviral drugs do NOT clear cellular reservoirs.

“HIV-infected people have to take drugs for their lifetime to keep virus under control.

“This trial shows for the first time that there may be a way to clear one of the main cellular reservoirs.

“This is a major step to the ultimate goal of curing HIV-1 infection.”

Ongoing analysis of trial data

The trial was designed to assess the safety and antiviral activity of three month’s dosing of BIT225 in combination with antiretroviral drugs in treatment-naïve HIV-positive subjects.

This was a double-blind, placebo-controlled study undertaken at trial sites in Thailand.

Preliminary analysis of the safety data has shown that BIT225 was well tolerated at the 200 mg once daily dose, with no severe adverse events or withdrawals.

Analysis of the trial data is ongoing.

Biotron aims to present detailed data at scientific conferences and to potential commercial partners in late 2018/early 2019.


(0)
(0)




Biotron Ltd (BITRF) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us